СИМДАКС на ресурсе PubMed

1. Levosimendan prevents doxorubicin-induced cardiotoxicity in time- and dose dependent manner: Implications for inotropy.

Efentakis P, Varela A, Chavdoula E, Sigala F, Sanoudou D, Tenta R, Gioti K, Kostomitsopoulos N, Papapetropoulos A, Tasouli A, Farmakis D, Davos CH, Klinakis A, Suter T, Cokkinos DV, Iliodromitis EK, Wenzel P, Andreadou I.

Cardiovasc Res. 2019 Jun 22. pii: cvz163. doi: 10.1093/cvr/cvz163. [Epub ahead of print]

PubMed: 31228183

2. Contribution of Levosimendan in Weaning from Mechanical Ventilation in Patients with Left Ventricular Dysfunction: A Pilot Study

Ifigeneia Kaltsi, Epameinondas Angelopoulos, Georgios Tzanis, Antonios Sideris, Konstantinos Tyrovolas, Stelios Kokkoris, Christina Gratziou, Serafeim Nanas, Christina Routsi

Critical Care Research and Practice Volume 2019, Article ID 7169492, 8 pages

https://doi.org/10.1155/2019/7169492

3. Rational discovery of dual-indication multi-target PDE/Kinase inhibitor for precision anticancer therapy using structural systems pharmacology.

Lim H, He D, Qiu Y, Krawczuk P, Sun X, Xie L

PLoS Comput Biol 2019;15(6): e1006619.

https://doi.org/10.1371/journal.pcbi.1006619

4. Levosimendan in patients with reduced left ventricular function undergoing isolated coronary or valve surgery.

van Diepen, Mehta RH, Leimberger JD, Goodman SG, Fremes S, Jankowich R, Heringlake M, Anstrom KJ, Levy JH, Luber J, Nagpal AD, Duncan AE, Argenziano M, Toller W, Teoh K, Knight JD, Lopes RD, Cowper PA, Mark DB, Alexander JH.

J Thorac Cardiovasc Surg. 2019 Jun 21. pii: S0022-5223(19)31278-4. doi: 10.1016/j.jtcvs.2019.06.020. [Epub ahead of print]

PubMed: 31358329

5. Treatments targeting inotropy.

Maack C, Eschenhagen T, Hamdani N, Heinzel FR, Lyon AR, Manstein DJ, Metzger J, Papp Z, Tocchetti CG, Birhan Yilmaz M, Anker SD, Balligand JL, Bauersachs J, Brutsaert D, Carrier L, Chlopicki S, Cleland JG, de Boer RA, Dietl A, Fischmeister R, Harjola VP, Heymans S, Hilfiker-Kleiner D, Holzmeister J, de Keulenaer G, Limongelli G, Linke WA, Lund LH, Masip J, Metra M, Mueller C, Pieske B, Ponikowski P, Ristic A, Ruschitzka F, Seferovic PM, Skouri H, Zimmermann WH, Mebazaa A,

Eur Heart J

PubMed:30295807

6. Short-term effects of levosimendan on strain/strain rate markers in patients with nonischemic dilated cardiomyopathy.

Kırış T, Avcı E

J Clin Ultrasound

PubMed:30229927

7. Levosimendan use in patients with preoperative low ejection fraction undergoing cardiac surgery: A systematic review with meta-analysis and trial sequential analysis.

Ng KT, Chan XL, Tan W, Wang CY

J Clin Anesth

PubMed:30172838

8. Levosimendan for Pediatric Anomalous Left Coronary Artery From the Pulmonary Artery Undergoing Repair: A Single-Center Experience.

Wang C, Gong J, Shi S, Wang J, Gao Y, Wang S, Peng YG, Song J, Wang Y

Front Pediatr

PubMed:30155453

9. Scheduled intermittent inotropes for Ambulatory Advanced Heart Failure. The RELEVANT-HF multicentre collaboration.

Oliva F, Perna E, Marini M, Nassiacos D, Cirò A, Malfatto G, Morandi F, Caico I, Perna G, Meloni S, Vincenzi A, Villani A, Vecchi AL, Minoia C, Verde A, De Maria R, RELEVANT-HF study group.

Int J Cardiol

PubMed:30131229

10. Intravenous Levosimendan and Vasopressin in New-Onset Acute Pulmonary Hypertension After Weaning from Cardiopulmonary Bypass.

Poidinger B, Kotzinger O, Rützler K, Kleinsasser A, Zierer A, Knotzer H

J Cardiothorac Vasc Anesth

PubMed:30122612